Osimertinib
An inhibitor of EGFR.
General information
Osimertinib is a tyrosine kinase EFGR receptor inhibitor. It is used for treatment of non-small cell lung cancer (LiverTox).
Osimertinib on DrugBank
Osimertinib on PubChem
Osimertinib on Wikipedia
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States
Preprint |
in silico | one of the top drugs and compounds identified by ViroTreat |
May/17/2020 | |
|
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19
Preprint In vitro Screening |
HeLa-ACE2 cells | Jun/16/2020 | ||
|
Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery
RdRpol Small molecule In silico |
in silico | 4.07 | Predicted to inhibit the SARS-CoV-2 RNA-dependent RNA polymerase via subpocket 1 binding. |
Sep/18/2020 |
